Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

The indications of immune checkpoint inhibitors (ICIs) are set to rise further with the approval of newer agent like atezolimumab for use in patients with advanced stage urothelial carcinoma. More frequent use of ICIs has improved our understanding of their unique side effects, which are known as im...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Front Pharmacol
Hoofdauteurs: Kumar, Vivek, Chaudhary, Neha, Garg, Mohit, Floudas, Charalampos S., Soni, Parita, Chandra, Abhinav B.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2017
Onderwerpen:
Pharmacology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5296331/
https://ncbi.nlm.nih.gov/pubmed/28228726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00049
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items